| Literature DB >> 34913882 |
Vivek Verma1,2, Gillian L Drury1, Marc Parisien1, Ayşe N Özdağ Acarli3,4, Tho-Alfakar Al-Aubodah5,6, Anastasia Nijnik7,8, Xia Wen1, Nicol Tugarinov1, Maria Verner9, Richie Klares1, Alexander Linton1, Emerson Krock10, Carlos E Morado Urbina10, Bendik Winsvold11,12,13, Lars G Fritsche14, Egil A Fors15, Ciriaco Piccirillo5,6, Arkady Khoutorsky1,9,16, Camilla I Svensson10, Mary A Fitzcharles1,17, Pablo M Ingelmo1,16, Nicole F Bernard6,18, Franck P Dupuy6, Nurcan Üçeyler4, Claudia Sommer4, Irah L King5,19, Carolina B Meloto1,9, Luda Diatchenko1,9,16.
Abstract
ABSTRACT: The pathophysiology of fibromyalgia syndrome (FMS) remains elusive, leading to a lack of objective diagnostic criteria and targeted treatment. We globally evaluated immune system changes in FMS by conducting multiparametric flow cytometry analyses of peripheral blood mononuclear cells and identified a natural killer (NK) cell decrease in patients with FMS. Circulating NK cells in FMS were exhausted yet activated, evidenced by lower surface expression of CD16, CD96, and CD226 and more CD107a and TIGIT. These NK cells were hyperresponsive, with increased CCL4 production and expression of CD107a when co-cultured with human leukocyte antigen null target cells. Genetic and transcriptomic pathway analyses identified significant enrichment of cell activation pathways in FMS driven by NK cells. Skin biopsies showed increased expression of NK activation ligand, unique long 16-binding protein, on subepidermal nerves of patients FMS and the presence of NK cells near peripheral nerves. Collectively, our results suggest that chronic activation and redistribution of circulating NK cells to the peripheral nerves contribute to the immunopathology associated with FMS.Entities:
Mesh:
Year: 2021 PMID: 34913882 PMCID: PMC8942876 DOI: 10.1097/j.pain.0000000000002498
Source DB: PubMed Journal: Pain ISSN: 0304-3959 Impact factor: 7.926